Related Experiment Video
Updated: May 7, 2026
12:40
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Treatment options for patients with poor clopidogrel response
Daniela I Roberts1, James J Nawarskas
1From the *New Mexico VA Health Care System and †University of New Mexico College of Pharmacy, Albuquerque, NM.
Cardiology in Review
|October 8, 2013
Summary
Many patients respond poorly to clopidogrel. Alternative treatments like switching to prasugrel or ticagrelor show some promise, but more research is needed to confirm clinical benefits for poor responders.
Area of Science:
- Pharmacology
- Cardiology
- Genetics
Background:
- A significant percentage of patients exhibit poor antiplatelet response to clopidogrel.
- Genetic testing (CYP2C19) and platelet function tests identify poor clopidogrel responders.
- Clinicians lack clear therapeutic strategies for managing patients with poor clopidogrel response.
Purpose of the Study:
- To review alternative therapeutic strategies for patients with poor clopidogrel response.
- To evaluate the pharmacologic benefits and clinical outcome data for clopidogrel alternatives.
- To identify areas requiring further research in managing clopidogrel non-responders.
Main Methods:
- Review of existing literature on alternative antiplatelet therapies.
- Comparison of pharmacologic effects of clopidogrel alternatives (prasugrel, ticagrelor, cilostazol, dose escalation).
- Analysis of available clinical outcome data for these alternatives.
Main Results:
- Alternative strategies (dose increase, switching, adding cilostazol) demonstrate greater antiplatelet effects pharmacologically.
- Early studies show no clear clinical benefit for increasing clopidogrel dosage or switching to prasugrel.
- Switching to prasugrel or ticagrelor shows potential benefit, particularly in patients with CYP2C19 loss-of-function variants.
Conclusions:
- Limited evidence supports current alternative strategies for poor clopidogrel responders.
- Switching to prasugrel or ticagrelor has the most potential, but requires more supporting data.
- Further research is essential to establish optimal treatment protocols for patients with poor clopidogrel response.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...